Not a trader, but assuming approval, I would expect we could move to $105 Or $110 by post Pom approval date (2/28). Then, IMO, we stay in the low 100's to 110 until the REV spm data is in and complete clarity exists on Euro application process (all, none, or patient subset submission).
If great results are reported, then who knows. But any earnings or clinical results positives are enhanced IMO, as this study is still the monkey on the back..
Either way, the pipeline presentation in May is well timed to either defuse the impact of disappointing results, or enhance on the positive side since everything would then be financially additive. (The timing of the presentation is another sign that the new team is thinking ahead proactively.)